Company intelligence / Profile preview

Synpac-Kingdom Pharmaceutical

Taipei, Taipei City, Taiwansynmosa.com.tw ↗

Ownership: Private
Development stage: Commercial

Overview

Synpac-Kingdom Pharmaceutical was a Taiwan-based pharmaceutical manufacturer specializing in high-barrier generic drugs and sterile injectable products. The company operated a cGMP-compliant plant audited by the US FDA, serving as a contract manufacturer for other pharma companies. In 2017, it was acquired by TWi Pharmaceuticals to expand their sterile product capacity. No proprietary clinical pipeline is reported post-acquisition.

Therapeutic areas: Other
Modalities: Small moleculeBiologic
Industry: Contract Manufacturing Organization

Partnerships

Dsm Sinochem Pharmaceuticals India Pvt., Ltd.

Beyond the preview

Go deeper on Synpac-Kingdom Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synpac-Kingdom Pharmaceutical.

Explore the full profile